Dr. Alex Kavros

VP, Business Optimisation and Innovation

Dr. Alex Kavros joined PrimeVigilance in March 2022 as VP of Business Optimisation and Innovation. Alex will oversee the development of innovation and corrective/disruption strategies to drive growth and spur investment.

Alex brings more than 16 years of drug development expertise in multiple technologies, therapeutic indications and clinical phases involving small molecules, biologics, combination products and ATMPs. His contributions have been strategic – helping to position companies for future growth and operational optimisation – as well as scientific – through consulting biotech and pharmaceutical clients on preclinical and clinical development and market approval.

Prior to joining PrimeVigilance, Alex held regulatory affairs and compliance consultancy and leadership positions in small and mid-size CROs and has previously worked for organisations such as Biotronik AG and Vifor Pharma Ltd in Switzerland.

Alex commenced his career as a researcher at Carnegie Mellon University, USA, following his doctoral studies in macromolecular/organic chemistry at Lancaster University, UK.

This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Cookie Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

  • __cfduid

Decline all Services
Accept all Services